The European Commission estimates that MSDs account for 50% of all absences from work lasting three (3) days or longer and for 60% of permanent work incapacity. This white paper looks at the business impact in Europe and the U.K., and how innovative companies are exploring bioelectrical options. Benchmark and new information: EHS/OHS professionals.

SPECIAL WHITEPAPER